The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus.
Anticancer therapeutics
Cancer management
Cosmeceuticals
Dermocosmetics
Oncodermatology
Skin toxicity
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
04 Nov 2023
04 Nov 2023
Historique:
received:
16
05
2023
accepted:
11
10
2023
medline:
6
11
2023
pubmed:
5
11
2023
entrez:
5
11
2023
Statut:
epublish
Résumé
Skin toxicities are very common in patients undergoing cancer treatment and have been found to occur with all types of cancer therapeutic interventions (cytotoxic chemotherapy, targeted therapies, immunotherapy, and radiotherapy). Further, skin toxicities can lead to interruption or even discontinuation of anticancer treatment in some patients, translating to suboptimal outcomes. Dermocosmetics (or cosmeceuticals)-defined as skincare solutions incorporating dermatologically active ingredients (beyond vehicle effects) that directly improve symptoms of various skin conditions-are increasingly being used in cancer care to prevent and manage skin toxicities. The active ingredients in these products have a measurable biological action in skin; they typically improve skin integrity (barrier function/hydration and other factors) while relieving skin symptoms. The Association Francophone des Soins Oncologiques de Support (AFSOS) and Multinational Association of Supportive Care in Cancer (MASCC) partnered to select a multidisciplinary group of healthcare professionals involved in the management of patients with cancer and skin toxicities. The group reviewed existing literature and created a summary of recommendations for managing these toxicities through online meetings and communication. In this publication, the group (1) reviews new skin toxicities seen with oncology drugs and (2) evaluates the role of dermocosmetics in improving patient outcomes and minimizing cancer treatment interruptions. We provide general recommendations for initiation and selection of skin care in all oncology patients as well as recommendations for what factors should be considered when using dermocosmetics in specific types of skin toxicities.
Identifiants
pubmed: 37925388
doi: 10.1007/s00520-023-08116-4
pii: 10.1007/s00520-023-08116-4
pmc: PMC10625513
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
672Informations de copyright
© 2023. The Author(s).
Références
Am Soc Clin Oncol Educ Book. 2020 May;40:485-500
pubmed: 32421446
J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1071-80
pubmed: 23368717
N Engl J Med. 2012 Feb 2;366(5):480-1
pubmed: 22296092
Dermatol Ther. 2011 Jul-Aug;24(4):401-10
pubmed: 21910798
Clin Case Rep. 2023 May 12;11(5):e7342
pubmed: 37192849
J Am Acad Dermatol. 2006 Sep;55(3):429-37
pubmed: 16908348
Eur J Cancer. 2007 Mar;43(5):845-51
pubmed: 17289377
Skin Pharmacol Physiol. 2007;20(5):253-9
pubmed: 17587889
J Drugs Dermatol. 2021 Dec 1;20(12):ss4-s14
pubmed: 34898158
Support Care Cancer. 2022 Dec;30(12):9681-9685
pubmed: 36274078
Breast Cancer (Dove Med Press). 2014 Aug 01;6:115-22
pubmed: 25114589
Indian Dermatol Online J. 2022 Jan 24;13(1):13-22
pubmed: 35198463
Cancer Res Treat. 2018 Oct;50(4):1186-1193
pubmed: 29237254
J Clin Oncol. 2010 Mar 10;28(8):1351-7
pubmed: 20142600
Radiother Oncol. 2012 Dec;105(3):378-9
pubmed: 22995589
J Drugs Dermatol. 2021 Sep 1;20(9):3ss-s19
pubmed: 34491030
Support Care Cancer. 2022 Nov;30(11):8655-8666
pubmed: 35655045
Cancer Nurs. 2022 Sep-Oct 01;45(5):378-386
pubmed: 34483284
Dermatol Ther. 2021 Jul;34(4):e14970
pubmed: 33984185
Ann Oncol. 2015 Oct;26(10):2017-26
pubmed: 26034039
Eur J Cancer. 2016 Dec;69:199-215
pubmed: 27855351
BMC Cancer. 2022 Sep 17;22(1):989
pubmed: 36115962
Am J Clin Dermatol. 2022 Jul;23(4):587-589
pubmed: 35788536
Oncology. 2007;72(3-4):152-9
pubmed: 18160805
J Eur Acad Dermatol Venereol. 2010 Apr;24(4):453-9
pubmed: 19793151
Support Care Cancer. 2006 Aug;14(8):802-17
pubmed: 16758176
Eur J Cancer Care (Engl). 2022 Nov;31(6):e13705
pubmed: 36130722
Br J Dermatol. 2009 Nov;161(5):1045-51
pubmed: 19558553
Dermatol Ther. 2022 May;35(5):e15412
pubmed: 35220635
Cancer Manag Res. 2013 Dec 09;5:401-8
pubmed: 24353440
J Am Acad Dermatol. 2020 Apr;82(4):994-996
pubmed: 31560981
Support Care Cancer. 2016 Feb;24(2):513-521
pubmed: 26111953
An Bras Dermatol. 2022 Jan-Feb;97(1):14-21
pubmed: 34844792
J Dermatol. 2023 Mar;50(3):357-363
pubmed: 36258256
Ann Oncol. 2012 Aug;23(8):1992-1998
pubmed: 22700992
Breast Cancer (Auckl). 2018 Jan 23;12:1178223417752772
pubmed: 29434476
Photodermatol Photoimmunol Photomed. 2007 Feb;23(1):42-5
pubmed: 17254038
Onco Targets Ther. 2018 Sep 17;11:5865-5872
pubmed: 30271169
Am J Clin Dermatol. 2018 Nov;19(Suppl 1):31-39
pubmed: 30374901
Dermatol Ther (Heidelb). 2022 Mar;12(3):683-699
pubmed: 35107817
Breast Cancer. 2023 Jan;30(1):2-12
pubmed: 36258148
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1340-1347
pubmed: 31856311
Clin Cosmet Investig Dermatol. 2021 Jun 14;14:623-632
pubmed: 34163201
Oncology (Williston Park). 2017 Dec 15;31(12):885-7, 894-9
pubmed: 29297172
J Eur Acad Dermatol Venereol. 2016 Jun;30(6):926-35
pubmed: 26916232
J Am Acad Dermatol. 2015 Apr;72(4):656-67
pubmed: 25637330
J Clin Oncol. 2015 Mar 10;33(8):894-900
pubmed: 25667293
Drug Des Devel Ther. 2020 Mar 02;14:951-959
pubmed: 32184564
Oncologist. 2021 Feb;26(2):e316-e326
pubmed: 33021006
Oncology (Williston Park). 2009 Feb;23(2):194, 196
pubmed: 19323302
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1303-8
pubmed: 20044218
Ann Oncol. 2021 Feb;32(2):157-170
pubmed: 33248228